Asset Details
Do you wish to reserve the book?
Regulatory cell therapy for kidney transplantation and autoimmune kidney diseases
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Regulatory cell therapy for kidney transplantation and autoimmune kidney diseases
Do you wish to request the book?
Regulatory cell therapy for kidney transplantation and autoimmune kidney diseases
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Regulatory cell therapy for kidney transplantation and autoimmune kidney diseases
2025
Overview
Regulatory cell therapies, including regulatory T cells and mesenchymal stromal cells, have shown promise in early clinical trials for reducing immunosuppression burden in transplantation. While regulatory cell therapies may also offer potential for treating autoimmune kidney diseases, data remains sparse, limited mainly to preclinical studies. This review synthesises current literature on the application of regulatory cell therapies in these fields, highlighting the safety and efficacy shown in existing clinical trials. We discuss the need for further clinical validation, optimisation of clinical and immune monitoring protocols, and the challenges of manufacturing and quality control under Good Manufacturing Practice conditions, particularly for investigator-led trials. Additionally, we explore the potential for expanding clinical indications and the unique challenges posed in paediatric applications. Future directions include scaling up production, refining protocols to ensure consistent quality across manufacturing sites, and extending applications to other immune-mediated diseases.
Graphical abstract
A higher resolution version of the Graphical abstract is available as
Supplementary information
Publisher
Springer Berlin Heidelberg,Springer,Springer Nature B.V
Subject
/ Autoimmune Diseases - immunology
/ Autoimmune Diseases - therapy
/ Cell- and Tissue-Based Therapy - methods
/ Cell- and Tissue-Based Therapy - standards
/ Cells
/ Child
/ Failure
/ Humans
/ Kidney Diseases - immunology
/ Kidney Transplantation - adverse effects
/ Kidneys
/ Medicine
/ Mesenchymal Stem Cell Transplantation - methods
/ Patients
/ Review
/ T-Lymphocytes, Regulatory - immunology
/ Urology
